Latest Transthyretin Stories
SAN DIEGO, Dec 9, 2014 /PRNewswire/ -- Arcturus Therapeutics Inc., a leading small interfering RNA (siRNA) and messenger
SAN DIEGO, Dec.
SAN DIEGO, Dec. 1, 2014 /PRNewswire/ -- Arcturus Therapeutics, Inc., a leading RNA medicines company pursuing orphan diseases, today announced that Joseph E.
SAN DIEGO, Nov.
- LUNAR-101, an UNA(TM) oligomer therapeutic for transthyretin-mediated familial amyloid cardiomyopathy (TTR-FAC), exhibited in non-human primates TTR reduction greater than 90% with a single low dose
CARLSBAD, Calif., Oct. 9, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
CARLSBAD, Calif., July 16, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
CARLSBAD, Calif., June 24, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
- Greater than 100-fold Allele-specific silencing of V30M variant for the treatment of Familial Amyloid Polyneuropathy (TTR-FAP) - SAN DIEGO, May 13, 2014 /PRNewswire/ --
Biotech Leadership with Significant Strategic and Financial Expertise SAN DIEGO, May 6, 2014 /PRNewswire/ -- Arcturus
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.